Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats

Neuroscience Letters

Volumn 584, Issue , 2015, Pages 276-281

  Suzuki, Syuuichirou ^a   Kawamata, Jun ^a   Iwahara, Naoyuki ^a   Matsumura, Akihiro ^a   Hisahara, Shin ^a   Matsushita, Takashi ^b   Sasaki, Masanori ^c   Honmou, Osamu ^c   Shimohama, Shun ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

6 Hydroxydopamine; Anti inflammatory; Mesenchymal stem cell; Neuroprotection; Parkinson's disease

Indexed keywords

CALCIUM ION; METHAMPHETAMINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CATECHOLAMINE SYNTHESIS; CELL ACTIVATION; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROGLIA; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; RAT; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; THERAPY EFFECT; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; GLIA; METABOLISM; PARKINSONIAN DISORDERS; PATHOLOGY; SPRAGUE DAWLEY RAT; STEREOTYPY;

ANIMALS; DOPAMINERGIC NEURONS; FEMALE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; METHAMPHETAMINE; NERVE DEGENERATION; NEUROGLIA; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84918586190     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.10.039     Document Type: Article

References (25)

1. Banati R.B., Daniel S.E., Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 1998, 13:221-227.
2. Cobo M., Anderson P., Benabdellah K., Toscano M.G., Munoz P., Garcia-Perez A., Gutierrez I., Delgado M., Martin F. Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis. Cell Transplant. 2013, 22:839-854.
3. Delgado M., Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J. 2003, 17:944-946.
4. Dezawa M., Kanno H., Hoshino M., Cho H., Matsumoto N., Itokazu Y., Tajima N., Yamada H., Sawada H., Ishikawa H., Mimura T., Kitada M., Suzuki Y., Ide C. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J. Clin. Investig. 2004, 113:1701-1710.
5. Dogrukol-Ak D., Banks W.A., Tuncel N., Tuncel M. Passage of vasoactive intestinal peptide across the blood-brain barrier. Peptides 2003, 24:437-444.
6. Dunkley P.R., Bobrovskaya L., Graham M.E., von Nagy-Felsobuki E.I., Dickson P.W. Tyrosine hydroxylase phosphorylation: regulation and consequences. J. Neurochem. 2004, 91:1025-1043.
7. Hebb A.O., Hebb K., Ramachandran A.C., Mendez I. Glial cell line-derived neurotrophic factor-supplemented hibernation of fetal ventral mesencephalic neurons for transplantation in Parkinson disease: long-term storage. J. Neurosurg. 2003, 98:1078-1083.
8. Hisahara S., Shimohama S. Toxin-induced and genetic animal models of Parkinson's disease. Parkinson's Dis. 2010, 2011:951709.
9. Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996, 72:355-363.
10. Inden M., Takata K., Nishimura K., Kitamura Y., Ashihara E., Yoshimoto K., Ariga H., Honmou O., Shimohama S. Therapeutic effects of human mesenchymal and hematopoietic stem cells on rotenone-treated parkinsonian mice. J. Neurosci. Res. 2013, 91:62-72.
11. Kim S.U., Park I.H., Kim T.H., Kim K.S., Choi H.B., Hong S.H., Bang J.H., Lee M.A., Joo I.S., Lee C.S., Kim Y.S. Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease. Neuropathology 2006, 26:129-140.
12. Kim Y.J., Park H.J., Lee G., Bang O.Y., Ahn Y.H., Joe E., Kim H.O., Lee P.H. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. Glia 2009, 57:13-23.
13. Lanza C., Morando S., Voci A., Canesi L., Principato M.C., Serpero L.D., Mancardi G., Uccelli A., Vergani L. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J. Neurochem. 2009, 110:1674-1684.
14. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37:1553-1561.
15. Park H.J., Lee P.H., Bang O.Y., Lee G., Ahn Y.H. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J. Neurochem. 2008, 107:141-151.
16. Paxinos G., Watson C. The Rat Brain in Streotaxic Coordinates 2009, Elsevier, London. 6th ed.
17. Quik M., O'Neill M., Perez X.A. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol. Sci. 2007, 28:229-235.
18. Rodriguez-Gomez J.A., Lu J.Q., Velasco I., Rivera S., Zoghbi S.S., Liow J.S., Musachio J.L., Chin F.T., Toyama H., Seidel J., Green M.V., Thanos P.K., Ichise M., Pike V.W., Innis R.B., McKay R.D. Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells 2007, 25:918-928.
19. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
20. Shimohama S., Sawada H., Kitamura Y., Taniguchi T. Disease model: Parkinson's disease. Trends Mol. Med. 2003, 9:360-365.
21. Suzuki S., Kawamata J., Matsushita T., Matsumura A., Hisahara S., Takata K., Kitamura Y., Kem W., Shimohama S. 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through alpha7 nicotinic acetylcholine receptor stimulation in rats. J. Neurosci. Res. 2013, 91:462-471.
22. Wang F., Yasuhara T., Shingo T., Kameda M., Tajiri N., Yuan W.J., Kondo A., Kadota T., Baba T., Tayra J.T., Kikuchi Y., Miyoshi Y., Date I. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci. 2010, 11:52.
23. Wirenfeldt M., Clare R., Tung S., Bottini A., Mathern G.W., Vinters H.V. Increased activation of Iba1+ microglia in pediatric epilepsy patients with Rasmussen's encephalitis compared with cortical dysplasia and tuberous sclerosis complex. Neurobiol. Dis. 2009, 34:432-440.
24. Yanagida T., Takeuchi H., Kitamura Y., Takata K., Minamino H., Shibaike T., Tsushima J., Kishimoto K., Yasui H., Taniguchi T., Shimohama S. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model. Neurosci. Res. 2008, 62:254-261.
25. Zheng W., Honmou O., Miyata K., Harada K., Suzuki J., Liu H., Houkin K., Hamada H., Kocsis J.D. Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. Brain Res. 2010, 1310:8-16.